Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Tenax Therapeutics Inc (TENX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.63-9.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TENX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash funds operations through 2027 | It expects cash to last through 2027. | Intact | Cash runs out before end of 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “However, in a prespecified analysis, patients with a baseline 6MWD below the trial median of 333 meters showed a 26.3-meter improvement compared to placebo (95% CI 6.0, 46.7; nominal p=0.0112).” “However, in a prespecified analysis, patients with a baseline 6MWD below the trial median of 333 meters showed a 26.3-meter improvement compared to placebo (95% CI 6.0, 46.7; nominal p=0.0112).” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
TENX is a high-risk, loss-making clinical-stage company whose long-term thesis depends on trial progress and future execution. The thesis state is watch: recent signals improved, but recent financial performance remains below its industry cohort.
The evidence provides no valuation comparison or clear account of what the market expects, so whether TENX is cheap, fair, or expensive versus peers is unclear. No fragility gates fired, which points to low identified fragility in the priced-in assessment, not to a firm valuation conclusion.
Near term, management delivered the Phase 3 LEVEL data milestone on schedule and extended the cash runway through mid-2028; progress on LEVEL-2 enrollment is mixed. A recent earnings beat and improved composite signal are constructive, while losses, high risk, and a 42% estimated miss probability make upcoming results worth watching.
Over the next several quarters, the thesis hinges on clinical progress, especially enrollment in LEVEL-2 and the implications of the LEVEL data. Near-term risks include a guidance cut and weaker jobs data, while continued strength from major Healthcare companies could support the sector backdrop.
Over a 1-3 year view, TENX has better funding visibility and has delivered a key trial milestone, but it remains a high-risk, loss-making story with uneven execution evidence. The long-term thesis depends on clinical progress and continued operational delivery. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS loss narrows toward consensus estimates | A supporting condition in Tenax Therapeutics Inc's published investment case. The stated target is EPS loss improves to about -$1.39 in 2027. | Broken | EPS loss worsens beyond -$1.44 in 2026 or -$1.39 in 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Share topline data from LEVEL study in Q3 2026 | Tenax plans to share study data in Q3 2026. | Intact | Data not shared by Q3 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “However, in a prespecified analysis, patients with a baseline 6MWD below the trial median of 333 meters showed a 26.3-meter improvement compared to placebo (95% CI 6.0, 46.7; nominal p=0.0112).” “However, in a prespecified analysis, patients with a baseline 6MWD below the trial median of 333 meters showed a 26.3-meter improvement compared to placebo (95% CI 6.0, 46.7; nominal p=0.0112).” Delivery assessment Nov 5, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.95 → $-1.45 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.95 | $12,900,000 | 4 / 6 |
| 2026-07-25 | $-1.95 | $12,900,000 | 4 / 6 |
| 2026-07-26 | $-1.95 | $12,900,000 | 4 / 6 |
| 2026-07-27 | $-1.92 | $12,900,000 | 4 / 6 |
| 2026-07-28 | $-1.92 | $12,900,000 | 4 / 6 |
| 2026-07-29 | $-1.45 | $0 | 6 / 9 |
| 2026-07-30 | $-1.91 | $12,900,000 | 5 / 9 |
| 2026-07-31 | $-1.91 | $12,900,000 | 5 / 9 |
| 2026-08-01 | $-1.91 | $12,900,000 | 5 / 9 |
| 2026-08-02 | $-1.46 | $0 | 6 / 9 |
| 2026-08-03 | $-1.46 | $0 | 6 / 9 |
| 2026-08-04 | $-1.46 | $0 | 6 / 9 |
| 2026-08-05 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-06 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-08 | $-1.46 | $0 | 6 / 9 |
| 2026-08-09 | $-1.46 | $0 | 6 / 9 |
| 2026-08-10 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-12 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-13 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-14 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-15 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-16 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-17 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-18 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-19 | $-1.90 | $12,900,000 | 5 / 9 |
| 2026-08-20 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-21 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-22 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-23 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-24 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-25 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-26 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-27 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-28 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-29 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-30 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-08-31 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-01 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-02 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-03 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-04 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-05 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-06 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-07 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-08 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-09 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-10 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-11 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-12 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-13 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-14 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-15 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-16 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-17 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-18 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-19 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-20 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-21 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-22 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-23 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-24 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-25 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-26 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-27 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-28 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-29 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-09-30 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-01 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-02 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-03 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-04 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-05 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-06 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-07 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-08 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-09 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-10 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-11 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-12 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-13 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-14 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-15 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-16 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-17 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-18 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-19 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-20 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-21 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-22 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-23 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-24 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-25 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-26 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-27 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-28 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-29 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-30 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-10-31 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-11-01 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-11-02 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-11-03 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-11-04 | $-1.45 | $12,900,000 | 6 / 9 |
| 2026-11-05 | $-1.45 | $12,900,000 | 6 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.